Phase III Adaptive Adaptive Stereostactic Body Radiotherapy (SBRT) With Dose Escalation for High-Risk Prostate Cancer

Inclusion Criteria

• •Male.
• •Age ≥ 18 years
• •ECOG (Eastern Cooperative Oncology Group) performance status 0-2
• •Histologically proven prostate adenocarcinoma, not previously treated
• •High-risk or very high-risk according to the National Comprehensive Cancer Network (NCCN) :
• •* T3a / T3b (proximal extension only),
• •* and/or ISUP (International Society of Urological Pathology) grade 4-5,
• •* and/or PSA (Prostate-Specific Antigen) 20ng/mL
• •Non-metastatic, as proven by Prostate Specific Membrane Antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and pelvic MRI (Magnetic Resonance Imaging) less than 2 months before starting hormone therapy
• •Normal testosterone levels prior to hormone therapy
• •Ability to give consent for inclusion in the study
• •Acceptance of treatment and monitoring modalities